Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with acute coronary syndrome: an optical coherence tomography study

Ting-yu Zhang  
Capital Medical University Affiliated Anzhen Hospital

Qi Zhao  
Capital Medical University Affiliated Anzhen Hospital

Ze-sen Liu  
Beijing LuHe Hospital

Chao-yi Zhang  
Beijing ZhongGuanCun Hospital

Jie Yang  
Capital Medical University Affiliated Anzhen Hospital

Kang Meng (✉️ 13611078067@163.com)  
Capital Medical University Affiliated Anzhen Hospital  https://orcid.org/0000-0003-3852-9199

Research article

Keywords: Monocyte-to-lymphocyte ratio, Optical coherence tomography, Plaque vulnerability

Posted Date: October 31st, 2019

DOI: https://doi.org/10.21203/rs.2.16673/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background The importance of monocyte-to-lymphocyte ratio (MLR) has been indicated in the initiation and progression of coronary artery disease (CAD). However, few previous researches demonstrated the relationship between MLR and plaque vulnerability. We aimed to investigate coronary plaque vulnerability in patients with acute coronary syndrome (ACS) by optical coherence tomography (OCT).

Methods A total of 72 ACS patients who underwent coronary angiography and OCT test in Beijing Anzhen hospital were included in this retrospective study. The plaque vulnerability and plaque morphology were assessed by OCT.

Results The coronary plaque in high MLR group exhibited more vulnerable features, characterizing as thinner thickness of fibrous cap (FCT) (112.37 ± 60.24 vs 153.49 ± 73.29 μm, P = 0.013), greater maximum lipid core angle (167.36 ± 62.33 vs 138.79 ± 56.37°, P = 0.010) and longer lipid plaque length (6.34 ± 3.12 vs 4.50 ± 2.21 mm, P = 0.041). A prominently negative liner relation was found between MLR and FCT (R = 0.225, P < 0.005). Meanwhile, the incidence of OCT-detected thin cap fibro-atheroma (TCFA) (44.7% vs 18.4%, P = 0.014) and plaque rupture (36.8% vs 13.2%, P = 0.017) were higher in high MLR group. Most importantly, multivariable logistic regression analysis showed MLR level was related to the presence of TCFA (OR: 3.316 95%CI: 1.448-7.593, P = 0.005). MLR level could differentiate TCFA with a sensitivity of 72.0% and a specificity of 66.1%.

Conclusion Circulating MLR level has potential value in identifying the presence of vulnerable plaque in patients with ACS. MLR, as a non-invasive biomarker of inflammation, may be valuable in revealing plaque vulnerability. Key words Monocyte-to-lymphocyte ratio, Optical coherence tomography, Plaque vulnerability

Background

As the most severe form of coronary artery disease (CAD), acute coronary syndrome (ACS) is the leading cause of mortality in recent decades. Development of a thrombus on the background of an atherosclerotic plaque rupture, which subsequently lead to arterial occlusion, is the major mechanism responsible for the majority of ACS. In recent years, it has been widely realized that it is plaque composition rather than plaque size or stenosis severity significant for plaque rupture and subsequent thrombosis [1]. Vulnerable plaques were described as plaques with thin fibrous caps and large lipid core.

Inflammation reaction plays a significant role in the occurrence and progress of atherosclerosis [2,3]. Previous researches have demonstrated that increased level of monocytes, neutrophils and decreased level lymphocytes have closely association with the cardiovascular adverse outcomes [4,5a]. Recently, Hanhua Ji, et al reported that monocyte-to-lymphocyte ratio (MLR) was an independent risk factor of the presence of CAD, and significantly associated with coronary lesion severity [6,7]. Furthermore, Chen H, et al reported that MLR was an independent predictor for major adverse cardiovascular event (MACE) in patients with non-ST segment elevated myocardial infarction (NSTEMI) [7]. It was also demonstrated that
increased MLR level was associated with higher morality in patients with acute heart failure \cite{8}. However, the relationship between the MLR level and plaque vulnerability has not been sufficiently evaluated. On account of high resolution (10μm), optical coherence tomography (OCT) can accurately identify the features of coronary atherosclerotic plaques and observe microstructure of coronary arteries such as fibrous cap, lipid nucleus and intravascular thrombosis of plaques. Meanwhile, OCT has advantages in differentiating the thin cap fibro-atheroma (TCFA) \cite{9,10}. In this regard, our present study aimed to identify the relationship between MLR level and plaque vulnerability evaluated by OCT in patients with ACS.

**Methods**

**Study population**

From May 2015 to May 2017, a total of 72 patients with ACS who underwent coronary angiography and OCT test in Beijing Anzhen hospital involved in this study. This clinical research was approved by the Ethics committee of Beijing Anzhen Hospital affiliated to the Capital Medical University, and all patients signed the informed consent form. We collected general data, laboratory examination and relevant treatment data of all patients. The definition of ACS included ST segment elevated myocardial infarction (STEMI), NSTEMI and unstable angina pectoris (UAP).

**Laboratory analysis**

For all patients, venous blood samples were tested by the laboratory of Beijing Anzhen hospital. The MLR value was measured as the ratio of monocyte counts to lymphocyte counts.

**Coronary angiography and analysis**

Coronary angiography (CAG) is performed through radial or femoral artery pathways. All patients received a loading dose of aspirin (300 mg) and clopidogrel (300 mg) at least 6 hours before angiography. The images were analysis by two cardiac doctors.

**OCT analysis**

OCT imaging was obtained using the commercially available, frequency-domain C7-XR OCT Intravascular Imaging System (St Jude Medical, St Paul, MN) and Dragonfly catheter (Light Lab Imaging, Inc). OCT images and measurements were analyzed using light Lab Imaging by two independent cardiac doctors. The indistinct OCT image and length of vessel images less 50mm was excluded.

OCT was used to identify the presence of fibrous plaques, lipid plaques, calcified plaques, macrophage infiltration, microchannels, cholesterol crystals, plaque rupture and thrombus, as well as the imaging characteristics of lipid plaques \cite{11-15}. Normal vascular structure as shown in figure 1A. Lipid plaque was
defined as a diffusely bordered, signal-poor region with an overlying signal-rich bands. Each plaque was at least 5mm apart from each other or at least 5mm away from the scaffold edge. When the lipid plaque was identified, the Lipid length was measured with the system's own measuring tool, and the Lipid core arc of the Lipid plaque was measured every 1mm. At the thinnest place of the lipid plaque fibrous cap, measured three times the thickness of the fibrous cap and calculated the average as the plaque thickness of fibrous cap (FCT). The length of the lipid plaque, maximum lipid core Angle (Max lipid arc), average lipid core Angle (Mean lipid arc) and lipid index (defined as average lipid arc times lipid plaque length) were recorded respectively. Thin cap fibroatheroma (TCFA) (as shown in figure 1B) was defined as a lipid plaque whose thickness of fibrous was less than 65 μm and whose lipid core was larger than two quadrants. Macrophages was defined as dots or bands with high reflection and strong attenuation, and they often form radial shadows after dots of high signal (as shown in figure 1C). Fibrous plaque was defined as a signal-rich region with scattering (as shown in figure 1D). Calcified plaques were defined as low-signal or non-uniform areas with sharp edges (as shown in figure 1E). The micro channel was defined as a 50–300μm, low-signal and sharp edge hollow-like structure, which needs to be observed in at least 3 continuous sections (as shown in figure 1F). Cholesterol crystals was defined as thin linear regions with high signal intensity and low attenuation. Plaque rupture was defined as the disruption of plaque fibrous cap continuity with cavity formation. Intracoronary thrombus was defined as a mass (diameter 250 μm) attached to the luminal surface or floating within the lumen.

**Statistical analysis**

All Statistical analyses were performed by SPSS 21.0. Measurement data in accordance with normal distribution was mean±standard deviation, the comparison between groups using t-Test. Non-normal distribution of the measurement data using the median (25th to 75th percentiles), the comparison between the group using Mann-Whitney U test. Counting data using example (%), the comparison between groups is X² test or Fisher exact test. Receiver operating characteristic (ROC) curve analysis was performed to examine the diagnostic value of MLR in predicting the OCT-detected TCFA. Liner regression analysis was used to assess the correlations between MLR and FCT. Multivariatelogistic regression analysis was carried out to identify the independent risk factors of the TCFA. Variables that had a clinically possible relation with TCFA or appeared to be significant in univariate model were introduced into multivariable analysis. Both were bilateral tests and p<0.05 were statistically significant.

**Results**

We finally enrolled 72 patients with 120 plaques in this study. ROC curve analysis showed that the cut-off value for MLR level was 0.21, with a sensitivity of 72.0% and specificity of 66.1% for predicting OCT-detected TCFA (ROC area under curve: 0.741, 95% CI: 0.619–0.864, p = 0.001). Based on the optimal cut-off value of MLR: 0.21, subjects were classified into two groups: low MLR group (MLR ≤ 0.21, 36 subjects with 61 plaques) and high MLR group (MLR > 0.21, 36 subjects with 59 plaques).
Baseline clinical characteristics

The baseline demographic and clinical characteristics between the two groups were shown in Tables 1 and 2. The patients in high MLR group showed higher ages (P = 0.005) and lower BMI values (P = 0.035). The proportion of previous dyslipidemia was lower in high MLR group (36.1% vs 61.1%, P = 0.034). Compared with the low MLR group, those with high MLR had higher CRP (P = 0.023), monocyte count (P < 0.001) and lower triglyceride level (P = 0.049), lymphocyte count (P < 0.001). There was no statistical significance in other index between two groups.

Coronary angiography and OCT image findings

No prominent difference was found in the number and characteristics of lesions between the high and low MLR group, as shown in Table 3.

76 vessels were screened and OCT images were recorded. OCT images showed that the ratio of TCFA (44.7% vs 18.4%, P = 0.014) and plaque rupture (36.8% vs 13.2%, P = 0.017) were higher in the high MLR group, as shown in Table 4. Meanwhile, the high MLR group showed thinner fibrous cap thickness (FCT) (112.37±60.24 vs 153.49 ± 73.29μm, P = 0.013), greater maximum lipid angle (167.36 ± 62.33 vs 138.79 ± 56.37°, P = 0.010) and longer lipid plaque length(6.34 ± 3.12 vs 4.50 ± 2.21mm,P = 0.041) than the low MLR group, as shown in Table 5. Furthermore, a prominently negative liner relation was found between MLR and FCT (R = 0.225, P < 0.005) (Figure 2).

Risk factors of TCFA

According to the presence of OCT-detected TCFA, patients were classified into TCFA group (25 patients) and non-TCFA group (47 patients). Patients with TCFA had significantly higher MLR level compared with those without TCFA (P = 0.001) (Figure 3). Multivariatelogistic regression analysis showed that MLR was the independent risk factor of TCFA, after adjusting for confounding factors (OR: 3.316, 95% CI: 1.448–7.593, p = 0.005), as shown in Table 6.

Discussion

In recent years, many advances have been made in the identification and prediction of coronary plaque stability using non-invasive biomarkers. Our trial was the first to use the OCT test to evaluate the relationship between MLR levels and coronary plaque vulnerability in ACS patients. In the present study of ACS patients with high MLR, coronary plaque presented more vulnerable features, characterizing as thinner FCT, greater maximum lipid angle and longer lipid plaque length. Meanwhile, the incidence of plaque rupture and OCT-detected TCFA were higher in high MLR group. And high MLR level was demonstrated to be an independent risk factor of TCFA.
MLR is the ratio of monocytes to lymphocytes and the combined indicator of the two inflammatory factors. As the major mechanism of atherosclerosis, inflammation response has a great impact on the occurrence and development of atherosclerosis lesions, and eventually result in plaque instability and severely adverse outcomes related to CAD\textsuperscript{[16,17]}. One general feature of atherosclerotic lesions is the presence of inflammatory cells, such as macrophages, T cells. Monocytes and lymphocytes in the leukocyte subtype are crucial cells in the inflammatory process. Previous studies have shown that monocytes are closely related to many vital steps in cardiovascular pathology and atherosclerosis. Macrophages, derived from the circulating monocytes, influence the initiation and progression of atherosclerotic plaque by participating foam cells formation and inducing the production of inflammatory cytokines, matrix metalloproteinases, and reactive oxidative species\textsuperscript{[18–20]}. A novel therapeutic target associated with monocytes phenotype modulation has been used for cardiovascular diseases prevention and treatment\textsuperscript{[21]}. Low lymphocyte count (LLC) has been found to be a critical factor in atherosclerotic progress where inflammation responses plays a vital role. A decrease in lymphocyte cells was related to worse clinical outcomes in patients with cardiovascular disease, especially ACS. Furthermore, it has been demonstrated that increased lymphocytes apoptosis has negative impact on ejection fraction, area of myocardial necrosis and microvascular function in patients with ACS, especially acute myocardial infarction (AMI)\textsuperscript{[22–24]}. As a combination of two different biomarkers of inflammation, MLR can provide additive value to the evaluation of cardiovascular diseases. It could be concluded that high monocytes, low lymphocytes or both are associated with higher risk of CAD. Meanwhile, MLR is a widely available, inexpensive, and non-invasive biomarker.

Coronary unstable plaques are more prone to plaque rupture with subsequent thrombogenesis leading to episodes of acute coronary syndrome. Lipid-rich plaques with thin fibrous caps are the highest-risk and most vulnerable plaque phenotype. The TCFA, which characterizes as thin fibrous cap and a great lipid angle, tends to cause major adverse cardiovascular events\textsuperscript{[25]}. OCT, as a high-resolution imaging modality, has great advantages in identifying TCFA and providing detailed information about the lipid plaque, such as FCT. Meanwhile, OCT enables in vivo visualization of plaque burden, plaque morphology and response to therapy. In the present study, the plaque in high MLR group showed more vulnerable characteristics which had more prone to plaque rupture, leading to the occurrence of adverse cardiac events. And a conspicuously negative relation was found between MLR and FCT. The measurement of the necrotic lipid core and the FCT play crucial roles in the dynamics of plaque destabilization. The pathophysiological mechanisms between elevated MLR and plaque vulnerability may be related to immune-inflammatory response\textsuperscript{[1–3]}. Inflammation, proteolysis, and decreased collagen fiber content are likely to lead to plaque rupture.

The presence of vulnerable plaques is the main cause of ACS\textsuperscript{[26]}. Previous study demonstrated that MLR level was independently with TCFA in the patients with stable angina. The vulnerable plaque was identified by intravascular ultrasound (IVUS), which cannot provide specific morphology characteristics of plaque, such as the thickness of plaque components\textsuperscript{[27]}. In this study, the advantage of OCT in identifying vulnerable plaques was utilized to provide a direct link between MLR and the vulnerability of coronary
atherosclerotic plaques in ACS patients, such as FCT and lipid core angle. The present study found the incidence of TCFA and plaque rupture were higher in high MLR group. After adjusting for potential confounding factors, MLR was an independent predictable factor of TCFA. Based on ROC curve analysis, the cut-off value for MLR level was 0.21, with a sensitivity of 72.0% and specificity of 66.1% for predicting TCFA. Compared with monocytes count or lymphocytes count, we considered that MLR, as a combination of two inflammatory indicators, may has a greater advantage in identifying plaque vulnerability in ACS patients.

**Study limitations**

The current study has several potential limitations. Firstly, this study was a small sample and single-center retrospective study, this was a major limitation and source of bias for the findings. More trials are needed to confirm this result. Secondly, we were concerned with atherosclerotic plaques in culprit vessels, but not non-target lesions. Thirdly, the study was a cross-sectional trial, but no follow-up data and prognostic implications were analyzed. Despite these limitations, this study firstly explored the value of MLR level in vulnerability to coronary plaque in ACS patients.

**Conclusion**

In conclusion, the coronary atherosclerotic plaques in high MLR group exhibited more vulnerable characteristics. Meanwhile, elevated MLR level was independently with OCT-detected TCFA in culprit vessels in patients with ACS. These results reflected that circulating MLR, as a noninvasive and widely available inflammation biomarker, may has a potential value for determining atherosclerotic plaque vulnerability in the setting of ACS.

**Abbreviations**

CAD: coronary artery disease; ACS: acute coronary syndrome; MLR: monocyte-to-lymphocyte ratio; MACE: major adverse cardiovascular event; NSTEMI: non-ST segment elevated myocardial infarction; OCT: optical coherence tomography; TCFA: thin cap fibro-atheroma; STEMI: ST segment elevated myocardial infarction; UAP: unstable angina pectoris; CAG: coronary angiography; FCT: thickness of fibrous cap; ROC: receiver operating characteristic; LLC: low lymphocyte count; AMI: acute myocardial infarction; IVUS: intravascular ultrasound.

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the ethics committee of the Beijing Anzhen hospital, Capital Medical University. And all patients signed the informed consent form.
Consent for publication
Not applicable.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
No funding was obtained for this study.

Authors’ contributions
Conceived and designed the study: TYZ and QZ. Data and images collection and analyzed: ZSL and CYZ. Quality control the study and revision: KM. Wrote the manuscript: TYZ, QZ and JY. All authors read and approved the final manuscript.

Acknowledgements
Not applicable.

References
[1] Prediman K, Shah. Inflammation and plaque vulnerability. Cardiovascular drugs and therapy, 2009;23(1):31–40.

[2] Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.

[3] Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. Intern Med. 2015;278:483–93.

[4] Kounis NG, Soufras GD, Tsigkas G, et al. White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease. Clin Appl Thromb Hemost. 2015; 21:139–43.
[5] Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk. Am Coll Cardiol. 2005;45:1638–43.

[6] Hanhua Ji1, Yang Li, et al. Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment. BMC Cardiovascular Disorders (2017) 17:90.

[7] Chen H, Li M, Liu L, et al. Monocyte/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients with non-ST-elevation myocardial infarction. Medicine (Baltimore). 2019 Jun, 98(26): e162–67.

[8] Silva N, Bettencourt P, Guimaraes JT. The lymphocyte-to-monocyte ratio: an added value for death prediction in heart failure. Nutr. Metab. Cardiovasc. Dis. 2015; 25(11): 1033–1040.

[9] Kume T, Akasaka T, Kawamoto T, et al. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J, 2006;755: e1–4.

[10] Sinclair H, Bourantas C, Bagnall A, et al. OCT for the identification of vulnerable plaque in acute coronary syndrome. JACC Cardiovascular Imaging, 2015 Feb;8(2):198–209.

[11] Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002;106: 1640–5.

[12] Jang IK, Tearney GJ, MacNeill B, et al. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111: 1551–5.

[13] Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007;50:933–9.

[14] Fujii K, Kawasaki D, Masutani M, et al. OCT assessment of thin-cap fibroatheroma distribution in native coronary arteries. J Am Coll Cardiol Img 2010; 3: 168–75.

[15] Lee T, Yonetsu T, Koura K, et al. Impact of coronary plaque morphology assessed by optical coherence tomography on cardiac troponin elevation in patients with elective stent implantation. Circ Cardiovasc Interv 2011;4:378–86.

[16] Alie N, Eldib M, Fayad ZA, et al. Inflammation, atherosclerosis, and coronary artery disease: PET/CT for the evaluation of atherosclerosis and inflammation. Clin Med Insights Cardiol. 2014;8:13–21.

[17] Kriszbacher I, Koppan M, Bodis J. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;353:429–30.

[18] Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7:77–86.
[19] Binder CJ, Shaw PX, Chang MK, et al. The role of natural antibodies in atherogenesis. J Lipid Res. 2005;46:1353–63.

[20] Register TC, Appt SE, Clarkson TB. Atherosclerosis and vascular biologic responses to estrogens: histologic, immunohistochemical, biochemical, and molecular methods. Methods Mol Biol. 2016;1366:517–32.

[21] Pamukcu B, Lip GY, Devitt A, et al. The role of monocytes in atherosclerotic coronary artery disease. Ann. Med. 42(6), 394–403 (2010).

[22] Nunez J, Nunez E, Sanchis J, et al. Prognostic value of leukocytosis in acute coronary syndromes: the cinderella of the inflammatory markers. Curr. Med. Chem. 2006;13(18):2113–2118.

[23] Tang TT, Yuan J, Zhu ZF, et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res. Cardiol. 2012;107(1):232.

[24] Nunez J, Minana G, Bodi V, et al. Low lymphocyte count and cardiovascular diseases. Curr. Med. Chem. 2011;18(21):3226–3233.

[25] Antonio Fernández-Ortiz, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. Journal of the American College of Cardiology, 1994, 23(7):1562–1569.

[26] Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–92.

[27] FanZ, et al. Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina. Biomark Med 2017 Nov.

Tables

Table 1 Baseline Characteristics
### Table 2 Laboratory Parameters

| Parameters                     | Low MLR\(n=36\) | High MLR\(n=36\) | P      |
|-------------------------------|-----------------|------------------|--------|
| Age, years                    | 51.72±12.21     | 59.58±10.74      | 0.005  |
| Male, n(%)                    | 26 (72.2%)      | 30 (83.8%)       | 0.257  |
| BMI/(kg/m²)                   | 26.55±2.94      | 25.03±3.06       | 0.035  |
| Smoking, n(%)                 | 18 (50.0%)      | 20 (55.6%)       | 0.637  |
| Hypertension, n(%)            | 24 (66.7%)      | 19 (52.8%)       | 0.230  |
| Diabetes mellitus, n(%)       | 12 (33.3%)      | 11 (30.6%)       | 0.800  |
| Dyslipidemia, n(%)            | 22 (61.1%)      | 13 (36.1%)       | 0.034  |
| LVEF, %                       | 66 ±60.5,70     | 63.5 ±58.25,66.75| 0.066  |
| Type of ACS, n(%)             |                 |                  |        |
| UAP                           | 30 (83.8%)      | 28 (77.8%)       | 0.551  |
| Non-ATEMI                     | 1 (2.8%)        | 4 (11.1%)        | 0.357  |
| STEMI                         | 5 (13.9%)       | 4 (11.1%)        | 1.0    |
| Prior PCI, n(%)               | 8 (22.2%)       | 4 (11.1%)        | 0.343  |
| Previous MI, n(%)             | 9 (25.0%)       | 3 (8.3%)         | 0.111  |
| Medical therapy               |                 |                  |        |
| Aspirin, n(%)                 | 36 (100.0%)     | 36 (100.0%)      | -      |
| P2Y12 receptor antagonist, n(%)| 36 (100.0%)     | 36 (100.0%)      | -      |
| Statin, n(%)                  | 36 (100.0%)     | 35 (97.2%)       | 1.0    |
| RAS blocker, n(%)             | 18 (50.0%)      | 17 (47.2%)       | 0.814  |
| β-blocker, n(%)               | 29 (80.6%)      | 24 (66.7%)       | 0.181  |
| CCB, n(%)                     | 9 (25.0%)       | 5 (13.9%)        | 0.234  |

MLR: monocyte to lymphocyte ratio, BMI: body mass index, ACS: acute coronary syndrome, UAP: unstable angina pectoris, STEMI: ST-segment elevation myocardial infarction, MI: myocardial infarction, LVEF: left ventricular ejection fraction, ASA: acetylsalicylic acid, RAS: renin-angiotensin system, CCB: calcium channel blocker
| Parameters                      | Low MLR\(n=36\) | High MLR\(n=36\) | P   |
|--------------------------------|-----------------|------------------|-----|
| Monocyte, \(\times 10^9/L\)    | 0.32±0.98       | 0.43±0.11        | 0.001 |
| Lymphocyte, \(\times 10^9/L\)  | 2.16±0.60       | 1.48±0.48        | 0.001 |
| Neutrophil, \(\times 10^9/L\)  | 3.54±2.51, 4.66±2.51 | 4.10±3.12, 5.18±0.064 |
| MLR                            | 0.15±0.11, 0.18±0.18 | 0.26±0.23, 0.36±0.001 |
| hs-CRP, mg/L                   | 0.84±0.47, 1.77±0.001 |
| Platelets, \(\times 10^9/L\)   | 224.67±49.14    | 216.28±44.24     | 0.349 |
| HGB, \(\times 10^9/L\)         | 146.5±136.25, 156.75±150.5 | 139±131.75, 150.5±0.083 |
| TG, mmol/L                     | 1.86±1.24, 2.89±0.47 | 1.30±1.09, 2.1±0.049 |
| TC, mmol/L                     | 3.99±3.41, 4.73±4.73 | 3.97±3.34, 4.40±0.700 |
| HDL-C, mmol/L                  | 0.98±0.82, 1.13±0.87 | 0.96±0.87, 1.21±0.448 |
| LDL-C, mmol/L                  | 2.44±0.69       | 2.37±0.67        | 0.654 |
| CREA, μmol/L                   | 72.26±13.25     | 69.93±10.54      | 0.131 |
| UA, μmol/L                     | 375.11±105.47   | 346.62±74.51     | 0.190 |
| GLU, mmol/L                    | 5.67±5.38, 6.46±5.09 | 5.85±5.09, 6.95±0.951 |
| HbA1C, %                       | 6.00±5.55, 6.7±5.70 | 5.80±5.70, 6.40±0.882 |
| HCY, μmol/L                    | 11.5±9.33, 15.3±9.05 | 12.25±9.05, 15.58±0.552 |

HGB: hemoglobin, TG: Triglyceride, TC: cholesterol, HDL-C: high-density-lipoprotein cholesterol, LDL-C: low-density-lipoprotein cholesterol, CREA: creatinine, UA: uric acid, GLU: glucose, HbA1C: Glycated hemoglobin, HCY: homocysteine, hs-CRP: highly sensitive highly sensitive C-reactive protein

Table 3 Angiographic Findings

| Parameters                     | Low MLR\(n=36\) | High MLR\(n=36\) | P   |
|-------------------------------|-----------------|------------------|-----|
| The number of lesion          |                 |                  | 0.127 |
| Single vessel lesion          | 17 ±47.2%       | 13 ±36.1%       |
| Two-vessel lesion             | 15 ±41.7%       | 12 ±33.3%       |
| Three-vessel lesion           | 4 ±11.1%        | 11 ±30.6%       |
| Ostial lesion                 | 2 ±5.6%         | 6 ±16.7%        | 0.260 |
| Total occlusion lesion        | 2 ±5.6%         | 1 ±2.8%         | 1.0  |
| Diffuse lesion                | 9 ±25%          | 13 ±36.1%       | 0.306 |

Table 4  Coronary plaques of OCT images
| Parameters                  | Low MLR\(n=38\) | High MLR\(n=38\) | P     |
|-----------------------------|-----------------|------------------|-------|
| Lipid plaque                | 61              | 59               | 0.879 |
| Vessel                      |                 |                  |       |
| LAD                         | 23 ±60.5%       | 21 ±55.3%        |       |
| LCX                         | 4 ±10.5%        | 4 ±10.5%         |       |
| RCX                         | 11 ±28.9%       | 13 ±34.2%        |       |
| RVD, mm                     | 3.57±2.03       | 3.56±1.08        | 0.989 |
| MLD, mm                     | 1.61±0.64       | 1.69±0.53        | 0.526 |
| DS, %                       | 75.87±12.41     | 72.98±13.24      | 0.330 |
| Fibrosis plaque, %          | 35 ±92.1%       | 32 ±84.2%        | 0.480 |
| TCFA, %                     | 7 ±18.4%        | 17 ±44.7%        | 0.014 |
| Calcium plaque, %           | 22 ±57.9%       | 21 ±55.3%        | 0.817 |
| Rupture plaque, %           | 5 ±13.2%        | 14 ±36.8%        | 0.017 |
| Macrophage, %               | 28 ±73.7%       | 30 ±78.9%        | 0.589 |
| Thrombus, %                 | 5 ±13.2%        | 7 ±18.4%         | 0.529 |
| Microchannel, %             | 24 ±63.2%       | 21 ±55.3%        | 0.484 |
| Cholesterol crystals, %     | 24 ±63.2%       | 30 ±78.9%        | 0.129 |

LAD: left anterior descending coronary artery, LCX: left circumflex coronary artery, RCA: right coronary artery, RVD: reference vessel diameter, MLD: minimum lumen diameter, DS: diameter stenosis, TCFA thin-cap fibroatheroma

### Table 5 Lipid plaque

| Parameters                           | Low MLR\(n=61\) | High MLR\(n=59\) | P     |
|--------------------------------------|-----------------|------------------|-------|
| maximum lipid core angle, °          | 138.79±56.37    | 167.36±62.33     | 0.010 |
| mean lipid core angle, °             | 112.38±43.94    | 124.39±42.01     | 0.129 |
| Lipid plaque length, mm              | 4.50±2.21       | 6.34±3.12        | 0.041 |
| lipid index                          | 548.05±287.61   | 822.00±464.27    | 0.051 |
| Fibrous cap thickness, μm             | 153.49±73.29    | 112.37±60.24     | 0.013 |

### Table 6 Logistic Regression Analysis of TCFA
| Variable   | β    | Wald | OR   | 95%CI       | P     |
|------------|------|------|------|-------------|-------|
| Age        | 0.247| 0.513| 1.28 | 0.651-2.518 | 0.474 |
| Gender(male)| 0.140| 0.124| 0.87 | 0.400-1.893 | 0.725 |
| Smoking    | 0.325| 0.468| 1.249| 0.660-2.363 | 0.660 |
| BMI        | 0.151| 0.221| 1.163| 0.619-2.187 | 0.639 |
| Hs-CRP     | 0.494| 1.930| 0.610| 0.304-1.225 | 0.165 |
| LDL        | 0.296| 0.845| 1.345| 0.715-2.529 | 0.358 |
| TC         | 0.223| 0.739| 1.294| 0.719-2.329 | 0.390 |
| MLR        | 1.199| 8.041| 3.316| 1.448-7.593 | 0.005 |

**Figures**

**Figure 1**

Coronary plaques of OCT images A. Normal vascular structure B. Thin cap fibroatheroma and arrow showed the thickness of fibrosis cap was 60μm C. Macrophages infiltration D. Fibrosis plaque E. Calcium plaque F. Microchannel group (47 patients) (P = 0.001).
Correlation analysis of monocyte-to-lymphocyte ratio (MLR) and fibrous cap thickness (FCT). The MLR was negatively associated with FCT ($R = 0.255, P = 0.005$).

Figure 2
Figure 3

Comparison of MLR levels between patients with and without TCFA. The MLR value of the TCFA group (25 patients) was significantly greater than the non-TCFA.